| Literature DB >> 32375397 |
Alicja Sznarkowska1, Sara Mikac1, Magdalena Pilch1.
Abstract
Viral-derived elements and non-coding RNAs that build up "junk DNA" allow for flexible and context-dependent gene expression. They are extremely dense in the MHC region, accounting for flexible expression of the MHC I, II, and III genes and adjusting the level of immune response to the environmental stimuli. This review brings forward the viral-mediated aspects of the origin and evolution of adaptive immunity and aims to link this perspective with the MHC class I regulation. The complex regulatory network behind MHC expression is largely controlled by virus-derived elements, both as binding sites for immune transcription factors and as sources of regulatory non-coding RNAs. These regulatory RNAs are imbalanced in cancer and associate with different tumor types, making them promising targets for diagnostic and therapeutic interventions.Entities:
Keywords: ERVs; HERVs; MHC class I; adaptive immunity; miRNAs; non-coding RNAs; viruses in evolution
Year: 2020 PMID: 32375397 PMCID: PMC7281430 DOI: 10.3390/cancers12051155
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
Figure 1Representation of the relationship of the Tree of Life (green dendrogram) to the virosphere (blue cloud). The blue dendrogram represents species-specific persisting viruses. Reprinted from [21] with permission.
Figure 2Major histocompatibility complex (MHC) locus structure.
Figure 3The MHC class I promoter region. Tissue-specific expression of MHC class I is mediated through the regulatory elements located in the distal promoter (overlapping enhancer and silencer located −800 and −700 bp upstream to the transcription start site) [112]. The basal transcription level is mediated by the minimal MHC class I core promoter sequence (located from −50 bp to +14 bp) [113]. The minimal core promoter is comprised of elements required for RNA polymerase complex binding including CCAAT box, a TATA-box, an Initiator (Inr)-like motif, and a Sp1-binding site. The inducible and constitutive expression of MHC is regulated by the proximal promoter elements, located −500 bp–50 bp upstream to the transcription start site. At the DNA level, the proximal promoter is comprised of four sequences (W/S, X1, X2, and Y boxes) called the ‘SXY module’, which is found in all MHC class I genes and is highly conserved across vertebrates [114,115]. The X1 box is bound by regulatory factor complex X (RFX), a constitutively expressed trimer composed of RFX5 (Regulatory Factor X 5), RFXAP (RFX-Associated Protein), and RFXANK (RFX containing three Ankyrin repeats). The X2 box and Y boxes of the SXY module are bound by cAMP-responsive element-binding protein (CREB), activating transcription factor 1 (ATF1) [116], and nuclear transcription factor Y (NFY) respectively. The factor(s) that interact with the W/S box are still to be determined. This complex set of protein-DNA and protein–protein interactions is crucial for the recruitment of the transactivator protein NLRC5 and the formation of an enhanceosome. HAT–histone acetylase; HDM–histone demethylase. Created with BioRender.
HLA class I altered phenotypes.
| Phenotype | Characteristics | Description |
|---|---|---|
| I | Total loss of HLA class I molecules | Low frequency in laryngeal carcinomas (10%), colorectal carcinomas (18%), and melanomas (17%), and higher in breast (52%), prostate (40%), and bladder (35%) carcinomas [ |
| II | Loss of an HLA class I haplotype | Produced by loss of heterozygosity (LOH) associated with chromosome 6.Incidence of this altered phenotype is 46% in cervix carcinomas, 15–49% in head and neck, 17% in colorectal carcinomas, and 14% in breast carcinomas [ |
| III | Loss of an HLA class I locus | Found when both products of HLA-A, -B, or -C loci are coordinately downregulated [ |
| IV | HLA class I allelic loss | This molecular defect has been reported in colorectal carcinoma LS411, with a chromosomal break point in the HLA-A11 allele [ |
| V | Compound phenotype | Requires a combination of at least two different alterations.Perea et al. recently reported a mechanism responsible for a total HLA class I loss in approximately 60% of studied small cell lung carcinoma samples. It is the combination of HLA haplotype loss together with a transcriptional downregulation of HLA-A, B and C genes [ |
| VI | Failure to respond to interferon (IFN) | This altered phenotype is found when tumor cells express basal levels of HLA class I antigens, but they do not respond to the stimulation of HLA class I expression with different cytokines, such as α and γ interferons (IFNs). For instance, the renal cell carcinoma Caki-2 does not have DNA-binding activity for IFN regulatory factor-1 or signal transducer and activator of transcription (STAT-1) [ |
| VII | Downregulation of classical HLA molecules (Ia) with aberrant expression of non-classical HLA molecules (Ib) | Based on unique HLA class I tissue distribution, that is used by the tumors to avoid both T and NK cell responses. It enables cancer cells to escape CTL responses by losing HLA-A, B, C. At the same time, these tumor cells, by engaging HLA-Ib molecules with NK inhibitory receptors, are resistant to NK lysis [ |